Epidermal Growth Factor Receptor Inhibitors for Treatment of Orbital Squamous Cell Carcinoma

Abstract

context of a known heritable condition, the heparin dose can be adjusted, as was done in our patient.In highly suspicious cases (or those with a previous adverse event), treatment modalities other than OAC may need to be considered.As OAC is adopted more widely, it is important for clinicians to be aware of these prothrombotic states, the adverse events associated with them, and how to prophylactically manage them.